Clinical Research Directory
Browse clinical research sites, groups, and studies.
Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma
Sponsor: AdventHealth
Summary
The goal of this observational study is to evaluate whether hepatic artery infusion pump (HAIP) chemotherapy can improve outcomes in patients with pancreatic or duodenal adenocarcinoma who have isolated or liver-dominant metastases after surgery and systemic chemotherapy. The main questions it aims to answer are: Does HAIP chemotherapy improve liver tumor response based on imaging criteria (RECIST)? What are the progression-free survival and overall survival outcomes in this patient population? Participants will: Undergo placement of a hepatic artery infusion pump as part of standard clinical care Receive floxuridine (FUDR)-based chemotherapy through the pump Have clinical data, imaging results, and laboratory markers (e.g., ctDNA, CEA, CA 19-9) collected from their medical records over time
Official title: Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma: A Prospective Feasibility Study
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
10
Start Date
2026-11-01
Completion Date
2028-05-02
Last Updated
2026-09-29
Healthy Volunteers
No
Conditions
Interventions
Hepatic Artery Infusion Pump (HAIP)
HAIP placement for metastatic disease to the liver
Floxuridine (FUDR)
FUDR-based chemotherapy
Locations (1)
AdventHealth Orlando
Orlando, Florida, United States